Female breast cancer surpasses lung as the most commonly diagnosed cancer worldwide

February 04, 2021

ATLANTA - FEBRUARY 4, 2021 - Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report, Global Cancer Statistics 2020, from the American Cancer Society (ACS) and the International Agency for Research on Cancer (IARC). Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease.

The article describes cancer incidence and mortality at the global level and according to sex, geography, and levels of social and economic development, and discusses associated risk factors and prospects for prevention for each of 10 major cancer types, representing more than 60% of the newly diagnosed cancer cases and more than 70% of deaths from cancer.

The report appearing in CA: A Cancer Journal for Clinicians, shows an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020. Female breast cancer was the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers.

The incidence of breast cancer is increasing in countries where rates of breast cancer have been historically low. "Dramatic changes in lifestyle and built environment have had an impact on the prevalence of breast cancer risk factors such as excess body weight, physical inactivity, alcohol consumption, postponement of childbearing, fewer childbirths, and less breastfeeding," the authors noted. "The increasing prevalence of these factors associated with social and economic transition results in a convergence toward the risk factor profile of transitioned countries and is narrowing international gaps in the breast cancer morbidity."

Death rates of breast cancer among women in transitioning countries were even higher compared with the rates among women in transitioned countries (15 and 12.8 per 100,000, respectively), despite the substantially lower incidence rates (29.7 and 55.9 per 100,000, respectively). "As the poor outcome in these countries is largely attributable to a late-stage presentation, efforts to promote early detection, followed by timely and appropriate treatment, are urgently needed through the implementation of evidence-based and resource-stratified guidelines," said Hyuna Sung, PhD, lead author of the report and Principal Scientist at the ACS.

Data show that lung cancer remained the leading cause of cancer death with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Lung cancer death rates are 3 to 4 times higher in transitioned countries than in transitioning countries, however, this pattern may well change as the tobacco epidemic evolves given that 80% of smokers reside in low- and middle- income countries. With about two-thirds of lung cancer deaths worldwide attributable to smoking, the disease can be largely prevented through effective tobacco control policies and regulations.

According to the report, an estimated 28.4 million new cancer cases are projected to occur in 2040, a 47% rise from 2020 globally. Transitioning countries are experiencing a larger relative increase in cancer incidence (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes. The authors state that this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. The authors warn that the growing rate of incidence could overwhelm health care systems, if left uncontrolled. Efforts to build a sustainable infrastructure for the dissemination of proven cancer prevention measures and the provision of cancer care in transitioning countries are critical for global cancer control.

Data in this report do not reflect the impact of the COVID-19 pandemic as they are based on cancer data collected in earlier years, and the full extent of the impact in different world regions is currently unknown. According to the report, delays in diagnosis and treatment, including suspension of screening programs and reduced availability of and access to care, are anticipated to cause a short-term decline in cancer incidence followed by increases in advanced-stage diagnoses and cancer mortality in some settings.

"The burden of cancer incidence and mortality is rapidly growing worldwide, and reflects both aging and growth of the population, as well as changes in the prevalence and distribution of the main risk factors for cancer, several of which are associated with socioeconomic development," said Freddie Bray, BSc(Hons), MSc, PhD, senior author of the report and Head of the Section of Cancer Surveillance at IARC. "Effective and resource-sensitive preventative and curative interventions are pertinent for cancer diagnosis. Tailored integration into health planning can serve to reduce the global burden of cancer and narrow the evident cancer inequities between transitioning and transitioned countries observed today."
-end-
Article: Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. doi: 10.3322/caac.21660.

URL upon embargo: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660

American Cancer Society

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.